Somaxon To Conduct Preclinical Tests On Its Phase III Insomnia Drug Silenor
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Somaxon will complete at least two preclinical studies before submitting a 505(b)(2) application for its insomnia product Silenor (doxepin), likely in the third quarter of 2007, the company said July 19.